Comparison of two different VMAT radiotherapy TPSs for pancreatic cancer using flattening filter free photon beam energy

Background: Pancreatic cancer is a devastating disease with a poor prognosis, and radiation therapy plays a crucial role in its treatment and management. Conventional radiation therapy (RT) techniques have limitations in delivering adequate doses to the tumor while sparing surrounding normal tissues. However, modern RT techniques such as intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic body radiation therapy (SBRT) have led to the development of novel approaches that can reduce toxicity. The incorporation of advanced imaging modalities, like four-dimensional computed tomography (4D-CT) and magnetic resonance imaging (MRI), enables enhancement of tumor control and improves conformality and treatment outcomes. Additionally, using flattening filter-free (FFF) beams can further enhance treatment efficiency and efficacy. Purpose: This study aims to compare two different VMAT techniques using two different treatment planning systems (TPSs), Monaco and Eclipse, in the treatment of pancreatic cancer II stage infiltrating duct carcinoma patients using an FFF photon beam. Materials and methods: 20 pancreatic cancer II stage infiltrating duct carcinoma patients were retrospectively analyzed, and each patient's plans were designed using the two TPSs. The dose distribution of the target using 6 MV FFF for TrueBeam-Varian and organs at risk (OARs) were compared. The monitor unit (MU), treatment time, conformity (CI), and homogeneity (HI) indices were also evaluated. Results: For pancreatic cancer patients, the mean dose of the planning target volume (PTV) in the Monaco plan was lower than the Eclipse plan. The plan evaluation parameters in Monaco and Eclipse were similar without significant differences (p-value = 0.152). The Monaco plan was better than the Eclipse plan regarding mean dose and V15Gy of the kidneys; the spinal cord was lowest in the Monaco plan, and the maximum dose and V45Gy of the spinal cord were 592.1 cGy and 1.37% lower than the Eclipse plan, respectively. Conclusion: The VMAT Monaco plan is a favorable TPS for pancreatic cancer patients, providing improved sparing of critical organs while maintaining adequate target coverage.